NASDAQ: AXDX - Accelerate Diagnostics, Inc.

Rentabilidad a seis meses: -45.18%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Accelerate Diagnostics, Inc.


Acerca de la empresa Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

más detalles
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

IPO date 1996-11-18
ISIN US00430H1023
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://acceleratediagnostics.com
Цена ао 1.06
Cambio de precio por día: 0% (1.08)
Cambio de precio por semana.: -9.24% (1.19)
Cambio de precio por mes: -17.56% (1.31)
Cambio de precio en 3 meses.: -34.94% (1.66)
Cambio de precio en seis meses: -45.18% (1.97)
Cambio de precio por año: +11.34% (0.97)
Cambio de precio en 3 años.: -56.63% (2.49)
Cambio de precio en 5 años.: -93.52% (16.67)
Cambio de precio en 10 años.: 0% (1.08)
Cambio de precio desde principios de año.: -9.24% (1.19)

Subestimación

Nombre Significado Calificación
P/S 4.48 4
P/BV -2.72 0
P/E 0 0
EV/EBITDA -1.6 0
Total: 4.25

Eficiencia

Nombre Significado Calificación
ROA, % -196.45 0
ROE, % 309.83 10
Total: 3.33

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.7561 10
Total: 9.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 29.67 4
Rentabilidad Ebitda, % -26.16 0
Rentabilidad EPS, % -68.08 0
Total: 0.8

Instituciones Volumen Compartir, %
Griffin Asset Management, Inc. 1219724 5.63
Vanguard Group Inc 306637 1.42
Birchview Capital, LP 225239 1.04
Cannell (Peter B.) & Company Inc 114690 0.53
Oracle Investment Management Inc 111575 0.52
Geode Capital Management, LLC 87003 0.4
Chartist, Inc. 68996 0.32
TCI Wealth Advisors, Inc. 58680 0.27
Blackrock Inc. 50842 0.23
Northern Trust Corporation 46119 0.21



Supervisor Título profesional Pago año de nacimiento
Mr. Jack Phillips CEO, President & Director 595k 1966 (59 años)
Mr. Lawrence Michael Mertz Chief Technology Officer 335.94k 1963 (62 año)
Mr. David Patience Chief Financial Officer 285.27k 1986 (39 años)
Ms. Maya Gowri Senior VP & Head of Operations N/A
Laura Pierson Investor Relations Officer N/A
Mr. John Meduri Chief Strategy Officer N/A
Mr. Chris Thode Senior Vice President of US Commercial N/A
Ms. Rita Boukamel Senior VP & Head of EMEA N/A

DIRECCIÓN: United States, Tucson. AZ, 3950 South Country Club Road - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://acceleratediagnostics.com